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Abstract	  12	   	  13	   Signaling	   pathways	   are	   essential	   intracellular	   networks	   that	   coordinate	  	  14	   molecular	   outcomes	   to	   external	   stimuli.	   Tight	   regulation	   of	   these	   pathways	   is	  15	   essential	   to	   ensure	   an	   appropriate	   response.	   microRNA	   (miRNA)	   is	   a	   class	   of	  16	   small,	   non-­‐coding	  RNA	   that	   regulates	  gene	  expression	  at	   a	  post-­‐transcriptional	  17	   level	  by	  binding	  to	  the	  complementary	  sequence	  on	  target	  mRNA,	  thus	   limiting	  18	   protein	  translation.	  Intracellular	  pathways	  are	  controlled	  by	  protein	  regulators,	  19	   such	   as	   Suppressor	   of	   Cytokine	   Signaling	   (SOCS)	   and	   A20.	   Until	   recently,	  20	   expression	   of	   these	   classical	   protein	   regulators	   was	   thought	   to	   be	   controlled	  21	   solely	  by	  transcriptional	  induction	  and	  proteasomal	  degradation;	  however,	  there	  22	   is	   a	   growing	  body	  of	   evidence	  describing	   their	   regulation	  by	  miRNA.	  This	  new	  23	   information	   has	   transformed	   our	   understanding	   of	   cell	   signaling	   by	   adding	   a	  24	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previously	  unknown	  layer	  of	  regulatory	  control.	  This	  review	  outlines	  the	  miRNA	  25	   regulation	  of	  these	  classical	  protein	  regulators	  and	  describes	  their	  broad	  effects	  26	   at	  both	  cellular	  and	  disease	  levels.	  We	  review	  the	  regulation	  of	  three	  important	  27	   signaling	   pathways,	   including	   the	   JAK/STAT,	   NF-­‐κB	   and	   TGF-­‐β	   pathways,	   and	  28	   summarize	  an	  extensive	  catalogue	  of	  their	  regulating	  miRNAs.	  This	  information	  29	   highlights	   that	   the	   importance	   of	   the	  miRNA	   regulon	   and	   reveals	   a	   previously	  30	   unknown	   regulatory	   landscape	   that	  must	   be	   included	   in	   the	   identification	   and	  31	   development	  of	  novel	  therapeutic	  targets	  for	  clinical	  disorders.	  	  32	   	  33	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Introduction	  38	   	  39	   microRNA	   (miRNA)	   are	   a	   class	   of	   small,	   non-­‐coding	  RNA	   of	   19-­‐25	   nucleotides	  40	   (nt)	   in	   length	   that	   regulate	   gene	   expression	   at	   a	   post-­‐transcriptional	   level	   by	  41	   binding	  to	  the	  3’UTR	  of	  the	  target	  transcript	  [1].	  They	  are	  transcribed	  in	  the	  form	  42	   of	   a	   primary	   transcript	   (pri-­‐miRNA),	   either	   under	   the	   control	   of	   their	   own	  43	   promoter	   regions	   or	   processed	   from	   a	   coding	   gene	   [2].	   pri-­‐miRNA	   are	  44	   subsequently	  processed	  in	  the	  nucleus	  by	  RNase	  III-­‐type	  endonuclease,	  Drosha,	  45	   in	  association	  with	  an	  accessory	  double-­‐stranded	  RNA	  (dsRNA)-­‐binding	  protein,	  46	   DiGeorge	   Critical	   Region	   8	   (DGCR8),	   into	   a	   stem-­‐loop	   dsRNA	   pre-­‐miRNA	   (or	  47	   precursor	  miRNA),	  of	  60-­‐70nt	  in	  length,	  with	  a	  2nt	  overhang	  at	  the	  3’	  end	  [3,	  4].	  48	   This	   stem-­‐loop	   dsRNA	   structure	   is	   transported	   from	   the	   nucleus	   to	   the	  49	   cytoplasm	  by	  Exportin-­‐5	  [5,	  6],	  where	  it	   is	   further	  processed	  by	  another	  RNase	  50	   III-­‐type	  endonuclease,	  Dicer,	  and,	  in	  some	  cases,	  also	  with	  the	  help	  of	  accessory	  51	   dsRNA-­‐binding	   proteins,	   PACT	   and	   TRBP,	   into	   a	   mature	   dsRNA	   duplex	   of	   19-­‐52	   21nt	  base	  pairs	  each	  side	  and	  a	  2nt	  overhang	  at	  each	  3’	  end	  [7,	  8].	  	  This	  duplex	  is	  53	   then	   loaded	   onto	   an	   effector	   complex	   called	   RNA-­‐induced	   silencing	   complex	  54	   (RISC).	  One	  strand	  from	  the	  duplex	  acts	  as	  a	  guide	  to	  direct	  RISC	  in	  binding	  the	  55	   target	  mRNA	  complementary	  sequence	  that	  mediates	  gene	  silencing	  [9]	  (Fig.1).	  	  56	   The	  discovery	  of	  microRNA	  in	  1993	  [10],	  revealed	  previously	  unknown	  layer	  of	  57	   post-­‐transcriptional	  control	   that	   revolutionized	  our	  concept	  of	  gene	  regulation.	  58	   “Classical”	  protein	  regulators,	  such	  as	  SOCS	  and	  A20,	  are	  well	  known	  to	  quickly	  59	   control	   signaling	  pathways	   through	  direct	  post-­‐translational	  modification,	   such	  60	   as	   phosphorylation	   or	   ubiquitination,	   of	   their	   target	   protein.	   miRNAs	   do	   not	  61	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regulate	   the	   activity	   of	   existing	   proteins,	   but	   rather	   limit	   the	   synthesis	   of	   new	  62	   proteins,	   providing	   an	   extra	   layer	   of	   control	   that	   is	   now	   accepted	   as	   being	   an	  63	   essential	   component	   of	   pathway	   regulation	   in	   processes	   such	   as	   cell	  64	   development	   or	   differentiation	   [11,	   12].	   However,	   as	   well	   as	   regulating	   key	  65	   players	  within	   signaling	  pathways,	  miRNAs	  are	   increasingly	  being	  documented	  66	   to	  regulate	  the	  “classical”	  regulators,	  thus	  providing	  additional	  control	  which	  we	  67	   review	  in	  this	  manuscript.	  Here	  we	  describe	  this	  novel	  mechanism	  of	  molecular	  68	   regulation	   of	   three	   major	   signaling	   pathways:	   Janus	   kinase/signal	   transducer	  69	   and	   activator	   of	   transcription	   (JAK/STAT),	   nuclear	   factor	   kappa-­‐light-­‐chain-­‐70	   enhancer	   of	   activated	   B	   cells	   (NF-­‐κB)	   and	   transforming	   growth	   factor	   beta	  71	   (TGFβ).	   We	   also	   outline	   how	   each	   miRNA	   plays	   a	   role	   in	   different	   cellular,	  72	   ranging	   from	   normal	   growth	   and	   development,	   and	   clinical	   contexts,	   such	   as	  73	   autoimmunity	  and	  cancer.	  In	  fact,	  this	  review	  clearly	  highlights	  that	  regulators	  of	  74	   the	  cellular	   signaling	  pathways	  are	   important	   targets	  of	   regulation	  by	  miRNAs,	  75	   and	  are	  significant	  targets	  for	  future	  research.	  76	   	  77	  
JAK-­‐STAT	  signaling	  pathway	  78	   	  79	   The	   JAK-­‐STAT	   signaling	   pathway	   is	   mainly	   adopted	   by	   cytokine	   receptors	   to	  80	   effect	   their	   anti-­‐viral,	   inflammatory	   and	   cell	   proliferative	   activity	   [13].	   Upon	  81	   binding	   of	   extracellular	   ligands,	   such	   as	   interferon	   (IFN)-­‐α/β	   and	   interleukin	  82	   (IL)-­‐6,	   to	   their	   respective	   dimerized	   transmembrane	   receptors,	   the	   pre-­‐83	   associated	  JAK	  tyrosine	  kinases	  are	  brought	  into	  juxtaposition	  and	  activated	  by	  84	   trans-­‐autophosphorylation.	   Activated	   JAK	   kinases	   then	   mediate	   tyrosine	  85	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phosphorylation	   on	   the	   conserved	   residue	   of	   the	   receptors,	   which	   causes	   the	  86	   receptor	  recruitment	  of	  SH2-­‐domain	  containing	  STAT	  proteins,	  which	  are	  in	  turn	  87	   phosphorylated	  by	  JAKs,	  dissociate	  from	  the	  receptors,	  dimerize	  and	  translocate	  88	   into	  the	  nucleus,	  where	  they	  act	  as	  transcriptional	  activators,	  driving	  expression	  89	   of	  effector	  genes	  	  [14].	  	  This	  pathway	  is	  central	  to	  the	  well	  being	  of	  our	  complex	  90	   immune	  system,	  with	  dysregulation	   leading	   to	  serious	   lymphoproliferative	  and	  91	   autoimmune	   diseases	   [13],	   and	   is	   therefore	   under	   tight	   regulation	   at	  multiple	  92	   levels	  [reviewed	  in	  15].	  	  93	   	  94	  
Regulation	  of	  SOCS	  by	  microRNAs	  95	   	  96	   The	  best	  studied	  regulators	  of	  the	  JAK-­‐STAT	  pathway	  are	  suppressor	  of	  cytokine	  97	   signaling	   (SOCS)	   proteins,	   which	   constitute	   a	   family	   of	   8	   members,	   including	  98	   SOCS1-­‐7	   and	   cytokine-­‐inducible	   Src	   homology	   2	   protein	   (CIS)	   [16].	   SOCS	  99	   proteins	   bind	   phosphorylated	   tyrosines	   of	   JAKs	   and/or	   the	   receptor	   via	   their	  100	   SH2-­‐domains,	  thus	  blocking	  STAT	  recruitment	  [14].	   	  Additionally,	  the	  SOCS	  box	  101	   domain	   recruits	   elongin	  B	   and	  C-­‐containing	  ubiquitin	  E3	   ligase	   complexes	   and	  102	   effectively	   mediates	   receptor	   degradation	   through	   the	   proteasome	   [14,	   15].	  103	   Basal	  expression	  of	  SOCS	  is	  low,	  but	  can	  be	  up-­‐regulated	  by	  cytokine	  stimulation,	  104	   providing	   an	   essential	   and	   effective	   negative	   feedback	   loop	   for	   the	   activated	  105	   pathway	   [16].	   Recent	   publications	   have	   documented	   that	  miRNA	   regulation	   of	  106	   SOCS	  expression	   is	  also	  key	   to	  optimal	  performance	  of	   the	   JAK/STAT	  pathway.	  	  107	   The	  role	  of	  miR-­‐155	  in	  regulating	  SOCS1	  protein	  expression	  has	  been	  implicated	  108	   across	  a	  spectrum	  of	  cell	  types	  in	  nearly	  20	  publications.	  It	  was	  first	  described	  by	  109	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Rudensky’s	  group	  in	  the	  context	  of	  Foxp3	  expression	  of	  regulatory	  T	  (Treg)	  cell	  110	   homeostasis.	   The	   authors	  noticed	   that	   an	  up-­‐regulation	  of	   SOCS1	  protein	   level	  111	   was	   detected	   in	   miR-­‐155-­‐deficient	   Treg	   cells,	   a	   phenotype	   which	   could	   be	  112	   reverted	  by	  the	  reintroduction	  of	  miR-­‐155	  [17].	  Not	  limited	  to	  T	  cell	  biology,	  the	  113	   regulatory	   role	   of	   miR-­‐155	   on	   SOCS1	   has	   also	   been	   implicated	   in	   NK	   cell	  114	   development	  and	  functions.	  In	  this	  study	  NK	  cells	  from	  miR-­‐155	  knockout	  mice	  115	   had	   elevated	   SOCS1	   expression,	   and	   suffered	   from	   both	   impaired	   NK	   cell	  116	   generation	  and	  response	  to	  viral	   infection	  [18].	  The	  functional	  consequences	  of	  	  117	   SOCS1	  regulation	  by	  miR-­‐155	  are	  best	  illustrated	  by	  early	  work	  from	  Cao’s	  group,	  118	   showing	   that	   even	   though	   miR-­‐155	   did	   not	   alter	   IFN	   expression	   in	   virally	  119	   infected	   macrophages,	   its	   suppression	   of	   SOCS1	   levels	   increased	   STAT1	  120	   phosphorylation	   and	   downstream	   IFN	   stimulated	   gene	   (ISG)	   induction	   [19].	  121	   Interestingly,	  the	  miR-­‐155-­‐SOCS1	  relationship	  has	  also	  been	  actively	  implicated	  122	   in	   the	   field	   of	   cancer	   biology.	   An	   inverse	   correlation	   of	   miR-­‐155	   and	   SOCS1	  123	   expression	  was	  observed	  in	  breast	  cancer	  patients	  and	  cell	   lines,	   in	  which	  miR-­‐124	   155	  conferred	  enhanced	  oncogenic	  properties	  [20].	  In	  hepatocellular	  carcinoma	  125	   (HCC),	   miR-­‐155	   regulation	   of	   SOCS1	   increases	   STAT3	   signaling,	   in	   turn	  126	   stimulating	  matrix	  metalloproteinase	  (MMP)9	  expression	  and	   increasing	  tumor	  127	   invasion	  [21].	  Other	  miRNAs	  that	  have	  been	  shown	  to	  regulate	  SOCS1	  expression	  128	   include	  miR-­‐30d	  in	  prostate	  cancer	  [22],	  miR-­‐122	  in	  Huh-­‐7	  hepatocyte	  cells	  [23]	  129	   and	  miR-­‐150	  in	  lupus	  nephritis	  pathogenesis	  model	  [24].	  The	  miR-­‐19a/b	  family	  130	   was	   up-­‐regulated	   in	   multiple	   myeloma	   (MM)	   and	   acted	   as	   an	   oncogenic	  131	   regulator	   via	   suppression	   of	   SOCS1,	   an	   important	   inhibitor	   of	   IL-­‐6-­‐mediated	  132	   growth	   in	   MM	   pathogenesis	   [25].	   The	   miR-­‐19a-­‐SOCS1	   relation	   has	   also	   been	  133	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implicated	   in	   gastric	   cancer	   [26].	   To	   our	   surprise,	   when	   we	   analyzed	   the	  134	   predicted	   targets	   of	  miR-­‐19a	  within	   the	   JAK-­‐STAT	   pathway	   by	   bioinformatics,	  135	   we	   discovered	   that	   the	  miR-­‐19a	   target	   sequence	   is	   conserved	   between	   SOCS1	  136	   and	  SOCS3,	  and	  found	  that	  SOCS3	  is	  a	  putative	  target	  of	  miR-­‐19a	  and	  modulates	  137	   the	  activity	  of	  JAK-­‐STAT	  signaling	  in	  response	  to	  IFN-­‐α	  and	  IL-­‐6	  [27].	   	  Together	  138	   these	   results	   demonstrate	   a	   realization	   of	   how	  evolution	  has	   “chosen”	   a	   single	  139	   miRNA	  species	  to	  regulate	  multiple	  cellular	  targets	  that	  converge	  onto	  the	  same	  140	   signaling	  pathway	  to	  exert	  an	  amplified	  combinatory	  effect	  on	  the	  pathway	  [12].	  141	   This	   broad	   effect	   of	   miR-­‐19a	   provides	   the	   cellular	   machinery	   with	   a	   very	  142	   convenient	  switch	  to	  control	  the	  expression	  of	  a	  set	  of	  genes	  with	  powerful	  effect.	  143	   While	  miR-­‐19a	  regulates	  multiple	  targets	  of	  the	  JAK-­‐STAT	  pathway	  its	  regulation	  144	   also	   extends	   to	   the	   NF-­‐κB	   signaling	   pathway	   [28].	   Similarly,	   miR-­‐155	   inhibits	  145	   SOCS1	  and	  SOCS3	  expression,	  which	  enhances	  IFN	  production	  during	  persistent	  146	   viral	   infection,	   demonstrating	   its	   ability	   to	   also	   control	   several	   SOCSs	   that	  147	   regulate	  more	  than	  one	  pathway	  [29].	  	  148	   	  149	   Targeting	   of	   SOCS	   by	   multiple	   miRNA	   also	   seems	   to	   be	   a	   common	   strategy	  150	   adopted	   by	   miRNA	   to	   regulate	   the	   JAK-­‐STAT	   pathway.	   miR-­‐203	   was	  151	   demonstrated	   by	   two	   independent	   groups	   to	   regulate	   SOCS3	   expression	   in	  152	   different	   cellular	   contexts.	   Ru	   and	   colleagues	   reported	   that	   miR-­‐203	   was	   up-­‐153	   regulated	  in	  breast	  cancer	  and	  its	  knock-­‐down	  correlated	  with	  enhanced	  level	  of	  154	   SOCS3	  expression	  and	  improved	  chemosensitivity	  towards	  cisplatin	  [30].	  Moffatt	  155	   and	   Lamont	   demonstrated	   that	   gingival	   epithelial	   cells	   infected	   with	  156	  
Porphyromonas	  gingivalis	  had	   increased	   cellular	  miR-­‐203	   expression,	   resulting	  157	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in	  SOCS3	  down-­‐regulation	  and	  enhanced	  STAT3	  activation	   [31].	  On	   top	  of	   this,	  158	   the	  latter	  showed	  that	  SOCS6	  is	  also	  a	  putative	  target	  of	  miR-­‐203	  [31].	  In	  another	  159	   example,	  although	  miR-­‐221	  was	  implicated	  in	  regulating	  SOCS3	  expression	  level,	  160	   which	   conferred	   anti-­‐tumorigenic	   effects	   in	   prostate	   cancer	   patients	   [32],	  161	   TargetScan	   also	   predicts	   that	   SOCS1	   and	   SOCS7	   are	   additional	   targets	   for	   this	  162	   miRNA	   [33],	   highlighting	   that	   our	   current	   knowledge	   and	   understanding	   of	  163	   SOCS-­‐targeting	  microRNAs	   is	   in	   its	   infancy	   and	   that	   future	   investigations	  may	  164	   reveal	   an	   even	   more	   complex	   and	   intricate	   network	   of	   intracellular	   pathway	  165	   regulation.	  	  166	   	  167	  
Regulation	  of	  PIAS	  by	  microRNAs	  168	   	  169	   While	   JAK	   kinase-­‐	   and	   receptor-­‐mediated	   signaling	   are	   directly	   regulated	   by	  170	   SOCSs,	  the	  downstream	  signaling	  protein,	  STAT,	  is	  regulated	  by	  protein	  inhibitor	  171	   of	  activated	  STAT	  (PIAS),	  which	  effectively	  fine-­‐tunes	  the	  pathway	  activity.	  The	  172	   PIAS	   family	   in	  mammals	   is	   composed	   of	   4	  members:	   PIAS1,	   PIAS3,	   PIASx	   and	  173	   PIASy,	  recognized	  to	  target	  STAT1,	  STAT3,	  STAT4	  and	  STAT1,	  respectively	  [15].	  174	   Each	  member	  of	  the	  PIAS	  family	  contains	  a	  RING-­‐finger-­‐like	  zinc-­‐binding	  domain	  175	   (RLD),	   which	   confers	   small	   ubiquitin	   like	   modifier	   (SUMO)	   E3-­‐ligase	   activity,	  176	   thus	  mediating	  SUMOylation	  and	  consequential	  deactivation	  of	  STATs	  [34].	  	  PIAS	  177	   protein	   also	   regulates	   STAT	   independently	   of	   SUMOylation.	  Other	  mechanisms	  178	   include	  direct	  blockage	  of	  STAT	  DNA	  binding	  and	  recruitment	  of	  co-­‐repressors,	  179	   such	   as	   histone	   deacetylase	   (HDAC)	   [reviewed	   in	   34].	   	   Although	   PIAS-­‐STAT	  180	   interaction	   is	   believed	   to	   be	   cytokine-­‐dependent	   [34],	   the	   recent	   discovery	   of	  181	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their	  regulation	  by	  miRNAs	  could	  be	  crucial	  in	  understanding	  the	  maintenance	  of	  182	   the	  pathway	  integrity	  and	  cellular	  homeostasis.	  183	   	  184	   Since	  PIAS3	  negatively	   regulates	   STAT3,	   a	   key	  player	   in	   the	   IL-­‐6-­‐mediated	   ISG	  	  185	   induction	   (driven	  by	   the	   IFN-­‐γ	   activated	   sequence	   [GAS]-­‐containing	  promoter)	  186	   [15],	   dysregulation	   of	   PIAS3	   by	   miRNA	   could	   have	   devastating	   outcomes.	  187	   Regulation	  of	  PIAS3	  by	  miRNA	  was	   first	  proposed	  by	  Brock	  et	  al.,	  who	  showed	  188	   that	  miR-­‐18a	  targeted	  the	  3’UTR	  of	  PIAS3	  mRNA,	  which	  suppressed	   its	  protein	  189	   expression	   and	   resulted	   in	   IL-­‐6-­‐induced	   STAT3	   activation	   in	   hepatocytes	   and	  190	   triggered	   the	   acute-­‐phase	   response	   [35].	   Since	   the	   dysregulation	   of	   JAK-­‐STAT	  191	   signaling,	   via	   altered	   expression	   of	   SOCS	  by	  miRNA,	   is	   evident	   in	  many	   cancer	  192	   models,	   it	   is	  no	  surprise	   to	  see	   it	   is	  equally	   true	   for	  PIAS.	   Indeed,	   regulation	  of	  193	   PIAS3	   by	  miR-­‐18a	   has	   been	   implicated	   in	   gastric	   adenocarcinoma,	   in	   which	   a	  194	   clinical	   correlation	   has	   been	   established	   between	   miR-­‐18a,	   PIAS,	   JAK-­‐STAT	  195	   pathway	   activity	   and	   downstream	   anti-­‐apoptotic	   and	   cell-­‐proliferative	   genes	  196	   [36].	  Using	  proteomics	  PIAS3	  was	  also	   identified	  as	  a	  cellular	   target	  of	  miR-­‐21,	  197	   which	   was	   highly	   expressed	   in	   MM	   [25],	   resulting	   in	   similar	   pathological	  198	   outcomes	   to	   IL-­‐6-­‐induced	   JAK-­‐STAT	   pathway	   activation	   [37].	   	   PIAS3	   is	   also	   a	  199	   target	   for	   miR-­‐125b	   in	   glioblastoma	   stem	   cells	   [38],	   further	   highlighting	   the	  200	   multifaceted	   nature	   of	   its	   regulation	   and	   importance	   as	   a	   gatekeeper	   of	  201	   oncogeneisis.	   Interestingly,	  microRNA	   regulation	   of	   PIAS3	   even	   controls	   T	   cell	  202	   development.	   In	   fact,	   inhibition	  of	  miR-­‐301a	  expression	   in	  myelin	  auto-­‐antigen	  203	   exposed	   CD4+	   T	   helper	   cells	   altered	   their	   cytokine	   expression	   profile	   and	  204	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hampered	   their	   differentiation	   into	   Th17	   cells,	   which	   was	   thought	   to	   be	  205	   controlled	  by	  PIAS3	  regulation	  of	  IL-­‐6-­‐STAT3	  signaling	  [39].	  	  206	   	  207	   Although	   there	   are	   4	   mammal	   PIAS	   proteins,	   evidence	   on	   their	   expression	  208	   regulated	  by	  miRNA	  has	  only	  been	  reported	   for	  PIAS3.	  This	  exclusivity	  may	  be	  209	   partly	  explained	  by	  the	  length	  of	  3’UTR	  of	  their	  mRNA,	  since	  only	  human	  PIAS3	  210	   mRNA	  carries	  3’	  UTR	  that	  spans	  for	  nearly	  1000nt	  long,	  while	  the	  others	  are	  just	  211	   a	   few	   hundred.	   This	   speculation	   is	   supported	   by	   the	   study	   that	   some	  212	   housekeeping	   genes	   which	   have	   strong	   preference	   to	   minimize	   miRNA	  213	   regulation	   tend	   to	  evolve	  with	  a	   shorter	  3’	  UTR,	   thus	  avoiding	  miRNA	  binding,	  214	   which	   consequently	   minimizes	   the	   risk	   of	   their	   accidental	   and	   undesirable	  215	   shutdown	  [40].	  However,	  the	  physiological	  relevance	  of	  the	  PIAS’s	  3’UTR	  length	  216	   in	  regulating	  the	  JAK-­‐STAT	  pathway	  warrants	  further	  investigation.	  In	  summary,	  217	   it	   is	   clear	   that	   the	   integrity	   of	   a	   functional	   JAK-­‐STAT	   pathway	   is	   essential	   for	  218	   cellular	  homeostasis.	  Dysregulation	  of	  this	  signaling	  by	  miRNA	  may	  attribute	  to	  219	   many	  cancers	  and	  autoimmune	  diseases.	  However,	  it	  is	  important	  to	  remember	  220	   that	   there	  are	  other	  signaling	  pathways,	  such	  as	   the	  NF-­‐κB	  and	  TGFβ	  cascades,	  221	   which	   also	   determine	   the	   outcome	   of	   effective	   cellular	   reactions	   and	   are	   now	  222	   known	  to	  be	  under	  the	  regulation	  of	  miRNAs.	  223	   	  224	  
NF-­‐κB	  signaling	  pathway	  225	   	  226	   NF-­‐κB	   mediates	   diverse	   biological	   processes	   at	   the	   cellular	   level,	   including	  227	   growth,	   development	   and	   inflammatory	   responses	   [41].	   The	   canonical	   NF-­‐κB	  228	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pathway	   mainly	   utilizes	   the	   RelA	   (also	   known	   as	   p65):p50	   heterodimer	   as	   a	  229	   transcription	   factor	   to	   activate	  downstream	   target	   genes.	   In	  unstimulated	   cells	  230	   the	   RelA:p50	   heterodimer	   is	   bound	   to	   inhibitor	   of	   NF-­‐κB	   (IκB),	   making	   it	  231	   inaccessible	  to	  the	  nucleus	  and	  thus	  blocking	  gene	  transcription	  [42].	  	  To	  remove	  232	   this	   suppressive	   constraint,	   IκB	  protein	  must	  be	  phosphorylated	  by	   IκB	  kinase	  233	   (IKK)	  complex,	  which	  constitutes	  two	  catalytic	  subunits,	  IKKα	  and	  IKKβ,	  and	  one	  234	   regulatory	   subunit,	   NF-­‐κB	   essential	   modulator	   (NEMO)	   (also	   known	   as	   IKKγ).	  235	   This	   initiates	  K48-­‐polyubiquitination	  and	   subsequent	  proteosomal	  degradation	  236	   of	  IκB	  protein	  [41].	  In	  the	  non-­‐canonical	  (or	  alternative)	  NF-­‐κB	  pathway,	  which	  237	   utilizes	   the	   RelB:p52	   heterodimer,	   p100,	   the	   p52	   predecessor,	   acts	   like	   IκB	   to	  238	   suppress	   translocation	  and	   transcription	  activation	  of	  RelB	  when	  bound	  under	  239	   unstimulated	   conditions	   [42].	   	   Upon	   activation,	   NF-­‐κB-­‐inducing	   kinase	   (NIK),	  240	   with	  the	  help	  of	  IKKα,	  induces	  phosphorylation	  of	  p100,	  which	  is	  then	  subjected	  241	   to	   ubiquitination	   and	   processing	   into	   p52,	   that,	   with	   RelB,	   serves	   as	   a	  242	   heterodimer	   transcription	   factor	   [reviewed	   in	   43].	   (Fig.2)	  Dysregulation	   of	   the	  243	   NF-­‐κB	   pathway	   accounts	   for	   many	   autoimmune,	   chronic	   inflammatory	   and	  244	   cancerous	   diseases	   [41],	   therefore,	   as	   with	   the	   JAK/STAT	   pathway,	   multiple	  245	   levels	  of	  regulation	  must	  be	  adopted	  to	  avoid	  disease	  [reviewed	  in	  41].	  246	   	  247	  
Regulation	  of	  PP2A/C	  by	  microRNAs	  248	   	  249	   Although	   the	   canonical	   and	   non-­‐canonical	   pathways	   mobilize	   different	   cell	  250	   modulators,	  they	  are	  regulated	  using	  a	  similar	  mode	  of	  action:	  phosphorylation,	  251	   ubiquitination,	   and	   then	   proteosomal	   processing	   of	   the	   inhibitory	   binding	  252	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partner	  of	  NF-­‐κB.	  Due	  to	  the	  importance	  of	  NF-­‐κB	  regulation,	  it	  is	  not	  surprising	  253	   to	  see	  that	  some	  of	  these	  steps	  are	  also	  controlled	  by	  miRNA.	  In	  both	  pathways,	  254	   IKKα/β	  is	  the	  major	  protein	  kinase,	  engaging	  in	  the	  initial	  phosphorylation	  and	  255	   subsequent	  processing	  or	  degradation	  of	  the	  inhibitory	  binding	  partner	  [42].	  	  In	  256	   order	  to	  become	  activated,	  IKKα/β	  complex	  requires	  trans-­‐autophosphorylation	  257	   and	   phosphorylation	   from	   another	   upstream	   kinase,	   such	   as	   TGF-­‐β	   activated	  258	   kinase-­‐1	   (TAK1)	   or	   NIK.	   These	   phosphorylation	   sites	   are	   subjected	   to	  259	   dephosphorylation	   by	   a	   group	   of	   protein	   phosphatases	   called	   PP2A/C	   [44].	  260	   Regulation	   of	   PP2A/C	   by	   miRNA	   is	   evident	   in	   cancer	   models.	   Two	   papers	  261	   recently	   reported	   that	   miR-­‐520h	   targets	   PP2A/C	   and	   promotes	   NF-­‐κB-­‐driven	  262	   tumorigenic	   gene	   expression	   in	   breast	   cancer	   and	   ovarian	   cancer	   cell	   lines,	   as	  263	   well	   as	   in	   lung	   cancer	   patient	   samples	   [45,	   46].	   The	   significance	   of	   regulating	  264	   PP2A/C	  is	  evident	  in	  the	  broad	  spectrum	  of	  miRNAs	  that	  control	  its	  expression,	  265	   including	  miR-­‐1,	   miR-­‐19,	   miR-­‐31	   and	  miR-­‐133.	  While	   these	   miRNAs	   have	   not	  266	   been	   shown	   to	   impact	   the	   NF-­‐κB	   pathway	   in	   disease	   models,	   they	   will	   most	  267	   likely	  affect	  responses	  to	  the	  pathway	  and	  thus	  identify	  an	  area	  of	  research	  that	  268	   warrants	  investigation	  [47-­‐49].	  269	   	  270	  
Regulation	  of	  CYLD	  by	  microRNAs	  271	   	  272	   Ubiquitination	   of	   target	   proteins	   is	   arguably	   one	   of	   the	   most	   important	   and	  273	   influential	  molecular	  events	  within	  a	  cell	  and	  is	  thereby	  controlled	  by	  a	  series	  of	  274	   processes.	   Polyubiquitnation	   does	   not	   only	   enable	   IκB	   degradation	   or	   p100	  275	   processing,	  but	  is	  implicated	  throughout	  the	  NF-­‐κB	  pathway	  [reviewed	  in	  50].	  	  In	  276	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the	  canonical	  pathway,	  NEMO	  undergoes	  K63-­‐polyubiquitination	  in	  response	  to	  277	   TNF	  stimulation,	  which	  facilitates	  the	  recruitment	  of	  upstream	  activating	  factors	  278	   and,	   in	   turn,	   the	  activation	  of	   IKK	  complex	  [51].	  To	  regulate	   IKK	  activation,	   the	  279	   tumor	   suppressor	   deubiquitinase,	   CYLD	   (cylindromatosis),	   removes	  280	   polyubiquitin	  chains	  from	  NEMO	  [42].	  	  But	  the	  regulation	  of	  CYLD	  is	  now	  known	  281	   to	   involve	  miRNA,	  which	   has	   been	   shown	   to	   play	   an	   important	   role	   in	   cancer	  282	   pathogenesis.	   For	   example,	   miR-­‐181b-­‐1	   was	   found	   to	   be	   up-­‐regulated	   in	   an	  283	   oncogenic	  Src	  kinase	  transformed	  model	  and	  manipulation	  of	  cellular	  miR-­‐181b-­‐284	   1	   levels	   altered	   CYLD	   expression,	   NF-­‐κB	   activity	   and	   mammary	   epithelial	   cell	  285	   line	   transformation	   [52].	   The	   targeting	   of	   CYLD	   by	   miR-­‐181b-­‐1	   was	   later	  286	   implicated	   in	   pancreatic	   cancer,	   in	   which	   increasing	  miR-­‐181b-­‐1	   levels	   confer	  287	   cell	   line	   chemoresistance	   to	   gemcitabine,	   via	   the	  down-­‐regulation	  of	  CYLD	  and	  288	   up-­‐regulation	  of	  NF-­‐κB	  activity	  [53].	  In	  gastric	  cancer	  patients	  miR-­‐362	  was	  up-­‐289	   regulated	   in	   tumor	   tissue	   samples,	   which	   inversely	   correlated	   to	   CYLD	  290	   expression,	  suggesting	  that	  miR-­‐362	  regulation	  of	  CYLD	  promoted	  NF-­‐κB	  activity	  291	   and	   subsequently	   enhanced	   cell	   proliferation	   and	   apoptotic	   resistance	   [54].	   In	  292	   addition,	  CYLD	  mRNA	  has	  been	   shown	   to	  be	  directly	   targeted	  by	  miR-­‐182	  and	  293	   miR-­‐486,	  which	  promoted	   tumor	  aggressiveness	  of	   gliomas,	   again	   through	  NF-­‐294	   κB	  dysregulation	   [55,	   56].	  The	  broad	   inhibitory	   remit	   of	   both	   these	  miRNAs	   is	  295	   clearly	  demonstrated	  in	  their	  spectrum	  of	  targets,	  with	  miR-­‐486	  also	  regulating	  296	   Cezanne	   (A20	   family	   deubiquitinase)	   and	   A20-­‐interacting	   partners,	   TNF-­‐α-­‐297	   induced	   protein	   3	   (TNFAIP3)	   interacting	   protein	   (TNIP)1/2/3;	   and	   miR-­‐182	  298	   regulating	   TNIP1,	   optineurin	   ubiquitin-­‐binding	   protein	   (OPTN),	   and	   the	  299	   deubiquitinase	  ubiquitin-­‐specific	  protease	  15	  (USP15)	  [55,	  56].	  300	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  301	  
Regulation	  of	  A20	  by	  microRNAs	  302	   	  303	   Another	  deubiquitination	  enzyme	  that	  has	  received	  much	  attention	  is	  A20	  (also	  304	   known	   as	   TNFAIP3,).	   A20	   contains	   an	   N-­‐terminal	   ovarian	   tumor	   (OTU)	  305	   deubiquintation	   domain	   and	   a	   C-­‐terminal	   zinc	   finger	   (ZnF)	   E3	   ligase	   domain,	  306	   which	   are	   thought	   to	   have	   dual	   functions	   in	   K63-­‐linked	   deubiquitination	   and	  307	   K48-­‐linked	  polyubiquitination	  of	  substrates,	  such	  as	  receptor-­‐interacting	  protein	  308	   (RIP)1	  kinase	  [57].	  	  RIP1	  is	  an	  upstream	  activating	  kinase	  of	  TAK1,	  and	  its	  K63-­‐309	   linked	  polyubiquitination	  is	  indispensible	  for	  IKK	  activation	  in	  the	  TNF-­‐induced	  310	   NF-­‐κB	   pathway	   [41].	   Indeed,	   A20	   mediates	   deubiquination	   of	   K63-­‐linked	  311	   polyubiquitin	   chain	   on	   RIP1,	   but	   K48-­‐linked	   polyubiquitination	   is	   actually	  312	   mediated	   by	   A20-­‐binding	   partner,	   ITCH	   (also	   known	   as	   itchy	   E3	   ubiquitin	  313	   protein	   ligase),	   which	   targets	   RIP1	   for	   proteosomal	   degradation,	   thus	  314	   terminating	   the	   transduced	   signal	   [42].	   (Fig.2)	   With	   its	   ability	   to	   negatively	  315	   regulate	   NF-­‐κB	   activity,	   A20	   is	   regarded	   as	   a	   tumor	   suppressor	   and	   its	  316	   inactivation	  is	  frequently	  observed	  in	  various	  cancer	  models	  [57].	   	  miRNA	  have	  317	   also	   been	   documented	   to	   manipulate	   A20	   expression	   levels	   with	   obvious	  318	   consequences	  for	  NF-­‐κB	  activity	  in	  tumor	  cells.	  	  319	   	  320	   Gantier	   and	   colleagues	   reported	   that	   global	   depletion	   of	   miRNA	   expression,	  321	   through	   conditional	   Dicer	   knock-­‐out,	   impaired	   pro-­‐inflammatory	   cytokine	  322	   induction	  [28].	  Initially	  using	  TargetScan	  they	  predicted	  that	  negative	  regulators	  323	   of	  NF-­‐κB,	  including	  A20	  and	  other	  related	  proteins,	  such	  as	  its	  binding	  partners	  324	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(Ring	   Finger	   Protein	   11	   (RNF11)	   and	   ITCH),	   A20	   regulator	   (TNIP1)	   and	   other	  325	   deubiquitinases	   (CYLD	   and	   Cezanne),	   were	   targets	   of	   an	   oncogenic	   miRNA	  326	   cluster,	  miR-­‐17-­‐92	   [28,	  33].	   	  Among	   the	   four	  miRNA	   families	   expressed	   in	   this	  327	   cluster,	  miR-­‐19	  was	  demonstrated	  to	  have	  a	  significant	  impact	  on	  NF-­‐κB	  activity	  328	   [28].	   In	   this	   study,	   A20	   and	   RNF11,	   as	   well	   as	   two	   other	   regulators	   of	   NF-­‐κB	  329	   (KDM2A	  and	  ZBTB16),	  were	  shown	  to	  be	  validated	  targets	  of	  miR-­‐19,	  whereas	  330	   the	   suppressive	   effect	   on	   other	   predicted	   targets,	   including	   CYLD,	   was	   not	  331	   observed	  [28].	  However,	  in	  T-­‐cell	  acute	  lymphoblastic	  leukemia	  (T-­‐ALL)	  patient	  332	   samples	   and	   cell	   lines,	   up-­‐regulation	   of	   miR-­‐19	   inhibited	   CYLD	   expression,	  333	   leading	   to	   sustained	   NF-­‐κB	   activity	   [58],	   clearly	   demonstrating	   that	   miRNAs	  334	   regulate	   multiple	   targets	   from	   the	   same	   pathway	   in	   a	   cell-­‐	   and	   disease-­‐type	  335	   dependent	   fashion	   and	   highlighting	   the	   vast	   chasm	   of	   knowledge	   still	   to	   be	  336	   explored.	  In	  addition,	  apart	  from	  miR-­‐19,	  miR-­‐146a	  was	  also	  able	  to	  regulate	  the	  337	   expression	   of	   RNF11,	   which	   facilitated	   Hendra	   virus	   replication	   in	   NF-­‐κB-­‐338	   dependent	  manner	  [59].	  miR-­‐18a,	  from	  the	  miR-­‐17-­‐92	  cluster,	  also	  reduced	  A20	  339	   in	   a	   model	   of	   rheumatoid	   arthritis	   (RA)	   and	   enhanced	   NF-­‐κB-­‐dependent	  340	   expression	  of	  the	  matrix	  degrading	  enzyme,	  MMP1,	  and	  inflammatory	  cytokines,	  341	   such	   as	   IL-­‐6,	   in	   synovial	   fibroblasts	   [60].	   Similar	   establishment	   of	   NF-­‐κB	  342	   dysregulation	   by	   miRNA-­‐targeting	   of	   A20	   was	   observed	   during	   Japanese	  343	   encephalitis	   virus	   infection.	   This	   virus	   induced	   cellular	   miR-­‐29b	   expression,	  344	   which	  regulated	  A20	  expression	   in	  a	  microglial	   cell	   line,	   thus	  enhancing	  NF-­‐κB	  345	   activity	   [61].	   In	   stark	   contrast,	   another	   miRNA	   from	   the	   same	  miR-­‐29	   family,	  346	   miR-­‐29c,	  was	   found	   to	  be	  down-­‐regulated	   in	  a	  Hepatitis	  B	  Virus	   (HBV)-­‐related	  347	   HCC	  cell	   line	  and	  patient	   samples.	  This	   loss	  of	  miR-­‐29	  expression	  up-­‐regulated	  348	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A20	  expression,	  resulting	  in	  restricted	  cell	  proliferation	  and	  enhanced	  apoptosis	  349	   [62].	   While	   miRNA	   are	   thought	   to	   predominately	   suppress	   target	   gene	  350	   expression,	   in	   a	   sarcoma	  model,	   miR-­‐29	   bound	   the	   A20	   3’UTR	   and	   prevented	  351	   physical	  association	  of	  an	  RNA-­‐binding	  protein	  HuR,	  thus	  protecting	  A20	  mRNA	  352	   from	   destabilization	   and	   degradation.	   In	   the	   same	   study,	   the	   authors	   showed	  353	   that	  miR-­‐125	  could	  also	  regulate	  A20	  expression	  [63],	  an	  observation	  mirrored	  354	   in	  a	  macrophage	  polarization	  and	  diffuse	  large	  B-­‐cell	  lymphoma	  model	  [64,	  65].	  	  355	   	  356	   In	   general,	   aberrant	   NF-­‐κB	   activity	   resulting	   from	   the	   dysregulation	   of	   its	  357	   regulator	   by	   miRNA	   drives	   the	   expression	   of	   numerous	   pro-­‐inflammatory	  358	   cytokines	  and	  chemoattractants	  at	  the	  site	  of	  injury,	  and	  confers	  aggressiveness	  359	   and	  apoptotic	   tolerance	  to	   tumors	  at	   the	  cellular	   level.	  These	  events	  have	  been	  360	   evident	  in	  many	  of	  the	  aforementioned	  examples	  and	  believed	  to	  be	  the	  center	  of	  361	   many	   inflammatory	   diseases	   and	   cancers.	   Therefore,	   further	   elucidating	   the	  362	   control	   of	   NF-­‐κB	   regulators	   by	   miRNA	   will	   help	   us	   better	   understand	   the	  363	   development	   and	   progression	   of	   these	   diseases	   and	   reveal	   much	   needed	  364	   therapeutic	  targets.	  365	  
	  366	  
TGFβ	  signaling	  pathway	  367	   	  368	   From	  the	  beginning	  of	  life	  the	  TGFβ	  pathway	  is	  indispensable	  in	  coordinating	  cell	  369	   development	   and	   differentiation	   and	   is	   essential	   for	   sustaining	   a	   functioning	  370	   immune	  response	  [66].	  The	  signal	  begins	  when	  functional,	  mature	  TGFβ	  is	  freed	  371	   by	  an	  endoprotease	   from	  a	   latent	   complex	  held	  within	   the	  extracellular	  matrix	  372	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[67].	   The	   binding	   of	   TGFβ	   to	   its	   cognate	   receptor	   complex,	   consisting	   of	   two	  373	   type-­‐I	   receptors	   and	   two	   type-­‐II	   receptors,	   triggers	   serine/threonine	   kinase	  374	   activity	   on	   the	   type-­‐II	   receptor	   molecule,	   which	   subsequently	   activates	   and	  375	   phosphorylates	   the	   type-­‐I	   receptor	  at	   its	  cytoplasmic	  domain	   [68].	   	  Smad2	  and	  376	   Smad3	   (Receptor	   (R)-­‐Smad	  proteins)	   are	   recruited	   to	   the	  phosphorylation	   site	  377	   and	   themselves	   phosphorylated	   by	   the	   activated	   type-­‐I	   receptor	   complex.	  378	   Phosphorylated	   Smad2/3	   can	   then	   form	   a	   trimeric	   complex	   with	   other	  379	   coactivators,	   such	   as	   Smad4	   and	   TIFIγ,	   to	   regulate	   gene	   expression	   in	   nucleus	  380	   [67].	   Alternatively,	   the	   receptor	   complex	   can	   activate	   a	   Smad-­‐independent	  381	   pathway	   through	   modulating	   Rho	   GTPase,	   MAP	   kinase	   and	   PI3K	   signaling	  382	   pathway	  activity,	  which	  regulates	  a	  different	  sets	  of	  target	  genes	  [66].	  (Fig.2)	  To	  383	   achieve	  optimized	  signaling	  activity,	  the	  TGFβ	  signaling	  pathway	  output	  is	  tightly	  384	   regulated	  at	  different	  stages.	  385	   	  386	  
Regulation	  of	  Smad7	  by	  microRNAs	  387	   	  388	   While	  R-­‐Smad	  proteins	   convey	  activating	  downstream	  signals,	   inhibitory	  Smad	  389	   (I-­‐Smad)	  proteins	  regulate	  this	  intracellular	  transduction.	  Smad7,	  for	  example,	  is	  390	   expressed	   in	   response	   to	   TGFβ	   pathway	   activation	   and	   provides	   efficient	  391	   negative	  feedback	  through	  several	  mechanisms	  [67].	  It	  can	  physically	  bind	  to	  the	  392	   type-­‐I	   TGFβ	   receptor,	   acting	   as	   a	   direct	   competitor	   to	   R-­‐Smad	   [67],	   or	   it	   can	  393	   further	   recruit	   other	   regulatory	   proteins,	   including	   PP1	   phosphatase	   and	   the	  394	   Smad	   ubiquitin	   regulatory	   factor	   (Smurf)	   E3	   ligase,	   which	   inactivate	   and	  395	   promote	   degradation	   of	   the	   receptor	   molecule,	   respectively	   [67,	   68].	  We	   now	  396	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know	   that	   expression	   of	   Smad7	   is	   regulated	   by	   multiple	   miRNAs.	   The	   up-­‐397	   regulation	  of	  miR-­‐21	  expression	  has	  been	  shown	  to	  suppress	  Smad7	  expression	  398	   in	   HCV-­‐infected	   liver	   biopsies.	   Interestingly,	   these	   findings	   correlated	   with	  399	   patient	  HCV	  load	  and	  fibrosis	  stage,	   indicating	  a	  role	  for	  miR-­‐21	  in	  accelerating	  400	   fibrogenesis	   [69].	   Others	   observed	   that	   miR-­‐21-­‐mediated	   reduction	   of	   Smad7	  401	   correlated	   with	   expression	   of	   TGFβ-­‐induced	   fibrotic	   markers,	   such	   as	   alpha	  402	   smooth	  muscle	  actin	  (α-­‐SMA)	  and	   fibronectin	  (Fn),	  which	  promoted	  epithelial–403	   mesenchymal	   transition	   (EMT)	   in	   lung	   fibrosis	   [70,	  71],	   renal	   fibrosis	   [72,	  73],	  404	   and	   systemic	   sclerosis	   	   [74,	   75].	   EMT	   also	   plays	   an	   important	   role	   in	   the	  405	   initiation	   of	   cancer	  metastasis.	   Complementary	   to	   this	   notion,	  miR-­‐21	  was	   up-­‐406	   regulated	   in	   the	   invasive	   ductal	   carcinoma	   region	   of	   breast	   cancer	   and	   knock-­‐407	   down	  of	  miR-­‐21	  restored	  Smad7	  levels	  in	  a	  breast	  cancer	  cell	  line	  [76].	  miR-­‐21-­‐408	   mediated	   reduction	   of	   Smad7	   expression	   has	   also	   been	   implicated	   in	   the	  409	   generation	   of	   carcinoma-­‐associated	   fibroblasts	   (CAFs),	   which	   confer	  410	   tumorigenesis,	   proliferation	   and	   invasiveness	   characteristics	   of	   tumors	   [77].	  411	   However,	   elevated	   miR-­‐21	   levels	   are	   not	   always	   associated	   with	   enhanced	  412	   proliferation	   and	   differentiation.	   In	   the	   case	   of	   myelodysplastic	   syndromes	  413	   (characterized	  by	   ineffective	   hematopoiesis),	   suppression	   of	   Smad7	  by	  miR-­‐21	  414	   was	   found	   to	   decrease	   erythroid	   colony	   formation	   of	   CD34+	   cells,	   while	  415	   inhibiting	  miR-­‐21	  could	  rescue	  red	  blood	  cell	  count	  and	  stimulate	  erythropoiesis	  416	   in	  transgenic	  mice	  [78].	  As	  seen	  with	  miR-­‐21,	  suppression	  of	  endogenous	  Smad7	  417	   is	   a	   common	   cancinogenic	   mechanism	   that	   promotes	   EMT.	   Other	   examples	  418	   include	   the	   miR-­‐216a/217	   cluster	   in	   HCC	   [79],	   miR-­‐20a	   in	   gall	   bladder	  419	   carcinoma	   [80],	   miR-­‐181a	   in	   ovarian	   cancer	   [81],	   and	   miR-­‐106b-­‐25	   in	   breast	  420	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cancer	   [82].	  While	   the	   oncogenic	   role	   of	   these	  microRNAs	  has	   been	  described,	  421	   the	   tumor	  suppressive	  role	  of	  a	  selection	  has	  also	  been	  reported,	  with	  reduced	  422	   miR-­‐25	  in	  colon	  cancer	  [83]	  and	  miR-­‐181c	  in	  metastatic	  neuroblastoma	  patients	  423	   [84].	   Interestingly,	   both	   reports	   reasoned	   that	   the	   tumor	   suppressive	   roles	   of	  424	   miR-­‐25	  and	  miR-­‐181c	  were	  accounted	  for	  by	  reduced	  Smad7	  protein	  expression	  425	   and	   TGFβ	   activity,	   which	   would	   otherwise	   stimulate	   tumor	   growth	   and	  426	   migration	  [83,	  84].	  	  427	   	  428	  
Regulation	  of	  Smurf	  by	  microRNAs	  429	   	  430	   Reduced	  Smad7	  expression	  in	  bronchial	  epithelial	  cells	  was	  also	  associated	  with	  431	   overexpressed	  miR-­‐15b	  in	  a	  chronic	  obstructive	  pulmonary	  disease	  model	  [85].	  432	   In	  their	  cell-­‐based	  assays,	  the	  authors	  also	  found	  that,	  apart	  from	  Smad7,	  Smurf2	  433	   expression	  was	  affected	  by	  miR-­‐15b	  [85].	  	  Smurf	  proteins	  are	  E3	  ubiquitin	  ligase	  434	   proteins,	   recruited	   by	   Smad7	   to	   the	   type-­‐I	   TGFβ	   receptor	   complex.	   Their	  435	   recruitment	   promotes	   proteosomal	   degradation	   of	   the	   receptor	   complex,	   thus	  436	   restricting	   signal	   transduction	   [86].	  Antagonizing	  miR-­‐322	  and	  miR-­‐503	  action	  437	   on	  Smurf2	  regulation	  was	  shown	  to	   inhibit	   the	  phosphorylation	  of	  Smad2	  [87].	  438	   As	   miRNA-­‐suppression	   of	   Smad7	   was	   observed	   in	   many	   cancers,	   it	   is	   not	  439	   surprising	   to	   see	   in	   an	   aggressive	   breast	   cancer	   model,	   Smurf2	   was	   down-­‐440	   regulated	   by	   miR-­‐15,	   miR-­‐16	   and	  miR-­‐128	   [88].	   miR-­‐15b	   also	   targets	   Smurf1	  441	   during	  osteoblast	  differentiation,	  as	  a	  way	  to	  activate	  the	  expression	  of	  a	  master	  442	   transcription	  factor,	  Runx2	  [89].	  Smurf1	  is	  also	  a	  target	  of	  miR-­‐17	  and	  miR-­‐497;	  443	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both	   of	   these	   studies	   showed	   reduced	   miRNA	   and	   up-­‐regulated	   Smurf1	  444	   expression	  in	  periodontitis	  and	  metastatic	  ovarian	  cancer,	  respectively	  [90,	  91].	  	  445	   	  446	  
Regulation	  of	  GARP	  by	  microRNAs	  447	   	  448	   TGFβ	   is	   secreted	   and	   stored	   in	   the	   extracellular	   matrix	   inside	   a	   large	   latency	  449	   complex.	   The	   cytokine	   remains	   inactive	   and	   bound	   to	   the	   latency-­‐associated	  450	   peptide	  until	  positive	   regulators	   increase	   the	  efficiency	  of	   its	  dissociation	   from	  451	   the	  large	  latency	  complex	  and	  it	  is	  processed	  into	  a	  mature	  form.	  Glycoprotein	  A	  452	   repetitions	   predominant	   protein	   (GARP),	   is	   expressed	   by	   T	   regulatory	   (Treg)	  453	   cells	   and	   tightly	   associated	   with	   the	   latency-­‐associated	   peptide	   bound	   to	  454	   immature	   TGFβ	   [67].	   GARP	   is	   essential	   for	   TGFβ	   activation	   [92],	   as	   it	   frees	  455	   immature	  TGFβ	  molecules	  from	  the	  latency	  complex	  [67].	  miR-­‐142-­‐3p	  regulates	  456	   GARP	  expression	  and	  thus	  controls	  Treg	  cell	  proliferation	  [93].	  Specifically,	   the	  457	   authors	  observed	  decreased	  expression	  of	  miR-­‐142-­‐3p	  in	  CD25+	  CD4	  T	  cells	  and	  458	   manipulation	  of	  miR-­‐142-­‐3p	  levels	  resulted	  in	  altered	  proliferation	  of	  these	  cells	  459	   [93],	   which	   is	   consistent	   with	   the	   concept	   of	   TGFβ-­‐mediated	   Treg	   cell	  460	   proliferation.	  No	  matter	  whether	  a	  miRNA	   is	   targeting	   the	  positive	  or	  negative	  461	   regulators	  of	  the	  TGFβ	  signaling	  pathway,	  any	  upset	  in	  the	  homeostatic	  balance	  462	   could	  lead	  to	  serious	  pathological	  consequences,	  like	  fibrosis	  or	  oncogenesis.	  463	   	  464	  
Regulation	  of	  microRNA	  levels	  465	  
	  466	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So	   far	   this	   review	  has	  discussed	  how	  miRNAs	  participate	   in	   signaling	  pathway	  467	   regulation	  and	  provide	  an	  additional	  layer	  of	  supervision	  on	  pathway	  regulators,	  468	   but,	   in	   order	   to	   fully	   understand	   how	   these	   “master	   regulators”	   control	   our	  469	   signaling	  networks	  it	  is	  important	  to	  note	  how	  miRNAs	  themselves	  are	  regulated.	  470	   Endogenous	   levels	   of	   miRNA	   are	   significantly	   linked	   to	   the	   final	   output	   of	  471	   signalling	  pathways	  and	  are	  under	  the	  control	  of	  several	  factors.	  The	  majority	  of	  472	   miRNAs	   is	   located	   in	   either	   intragenic	   or	   intergenic	   regions	   and	   is	   transcribed	  473	   together	   with	   its	   host	   gene	   or	   from	   its	   own	   promoter	   [2].	   The	   miR-­‐106b-­‐25	  474	   cluster	   is	  an	  example	  of	   intragenic	  miRNA,	  which	  sits	   itself	  within	   intron	  13	  of	  475	   the	   miniature	   chromosome	   maintenance	   7	   (MCM7)	   gene	   [94].	   This	   miRNA	  476	   cluster	   encodes	   three	  miRNAs,	   namely	  miR-­‐106b,	  miR-­‐93,	   and	  miR-­‐25,	   two	   of	  477	   which,	  miR-­‐106b	  and	  miR-­‐25,	  we	  described	  above	  as	  regulators	  of	  Smad7.	  These	  478	   miRNA	   were	   found	   to	   be	   frequently	   co-­‐expressed	   and	   probably	   co-­‐regulated	  479	   with	   their	   host	  mRNA	   [95]	   and	   amplification	   of	   the	  MCM7	   gene	   locus	   and	   its	  480	   elevated	  expression	  with	  miR-­‐106b-­‐25	  cluster	  have	  been	  associated	  with	  human	  481	   malignancies	   [94,	   96].	   The	  miR-­‐17-­‐92	   cluster	   (also	   known	   as	   oncomir-­‐1)	   is	   an	  482	   example	  of	  intergenic	  miRNA	  that	  is	  expressed	  and	  processed	  from	  the	  C13orf25	  483	   transcript	  [96].	  This	  miRNA	  cluster	  encodes	  six	  mature	  miRNAs,	  namely	  miR-­‐17,	  484	   miR-­‐18a,	  miR-­‐19a,	  miR-­‐20a,	  miR-­‐19b-­‐1,	  and	  miR-­‐92-­‐1,	  which	  have	  broad	  effects	  485	   on	  multiple	  pathway	  regulators,	  including	  SOCS,	  PIAS,	  A20,	  Smad7	  and	  Smurf1.	  	  486	   	  487	   It	   is	   interesting	   to	   note	   that	   the	   expression	   of	   both	   MCM7/miR-­‐106b-­‐25	   and	  488	   miR-­‐17-­‐92	  genes	  are	   induced	  by	  common	   transcription	   factors,	  E2F1	  and	  MYC	  489	   [96].	   E2F1	   and	   MYC	   are	   involved	   in	   a	   positive	   feedback	   loop	   making	   both	  490	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proteins	  capable	  of	  regulating	  one	  another	   [97].	  The	  entire	  regulatory	  network	  491	   may	   be	   further	   complicated	   by	   the	   negative	   regulation	   of	   E2F1	   expression	   by	  492	   miR-­‐106b	   and	   miR-­‐20a	   [96].	   These	   constitute	   an	   important	   regulatory	  493	   mechanism	   that	   allows	   these	  miRNAs	   to	   be	   expressed	   at	   optimized	   level.	   It	   is	  494	   foreseeable	  that	  in	  the	  event	  of	  sub-­‐optimal	  miRNA	  levels,	  the	  negative	  feedback	  495	   constrain	   is	   lenient,	   so	   the	   positive	   feedback	   loop	   of	   the	   transcription	   factors	  496	   encourages	   the	   expression	   of	   these	   miRNAs.	   Alternative,	   when	   miRNA	  497	   expression	  becomes	  excessive,	  it	  places	  a	  heavy	  negative	  feedback	  constrain	  on	  498	   the	   transcription	   factors,	   so	   that	   the	   continuous	   expression	   of	   miRNA	   can	   be	  499	   eventually	  shut	  off.	  Therefore,	  it	  is	  evident	  that	  the	  sequence	  of	  molecular	  events	  500	   responsible	   for	   miRNA	   expression	   can	   be	   more	   complex	   than	   their	   simple	  501	   regulation	  of	  target	  genes	  and	  networks,	  and	  hence	  should	  be	  analysed	  case	  by	  502	   case.	   In	  fact,	  when	  considering	  the	  mechanisms	  that	  alter	  the	  steady-­‐state	   level	  503	   of	   any	  miRNA,	  we	   should	   also	   take	   into	   account	   the	   cell	   type,	   its	   half-­‐life	   and	  504	   transient	  intracellular	  turnover	  [reviewed	  in	  98].	  	  505	  
	  506	  
Insights	  derived	  from	  regulator-­‐targeting	  miRNAs	  507	  
	  508	   Although	   the	   role	   played	   by	   each	   miRNA	   appears	   to	   be	   context-­‐dependent	   in	  509	   individual	   studies,	   some	   have	   collectively	   demonstrated	   its	   versatility	   in	  510	   regulating	  multiple	  regulators	  of	  a	  signaling	  pathway.	  Examples	  include	  miR-­‐15	  511	   (targeting	   Smad7,	   Smurf1	   and	   Smurf2	   in	   TGFβ	   pathway)	   [85,	   88,	   89],	   miR-­‐19	  512	   (targeting	  SOCS1	  and	  SOCS3	  in	  JAK-­‐STAT	  pathway;	  A20,	  CYLD	  and	  RNF11	  in	  NF-­‐513	   κB	   pathway)	   [25-­‐28,	   58],	   miR-­‐155	   (targeting	   SOCS1	   and	   SOCS3	   in	   JAK-­‐STAT	  514	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pathway)	  [29],	  miR-­‐203	  (targeting	  SOCS3	  and	  SOCS6	  in	  JAK-­‐STAT	  pathway)	  [30,	  515	   31].	  This	  versatility	  is	  indeed	  conferred	  by	  the	  ability	  of	  miRNA	  to	  regulate	  gene	  516	   expression	   at	   translation	   level	   by	   binding	   to	   and	   targeting	   the	   complementary	  517	   sequence	   present	   on	   3’	   UTR	   of	   any	   gene,	   irrespective	   of	   their	   actual	   protein	  518	   coding	  sequence,	  such	  that	  multiple	  genes	  that	  share	  similar	  gene	   function	  and	  519	   acquire	  the	  same	  complementary	  sequence	  can	  be	  regulated	  simultaneously	  by	  a	  520	   common	  miRNA.	  The	  miRNA-­‐target	  relationship	  is	  now	  thought	  to	  be	  under	  tight	  521	   natural	  selection	  and	  is	  believed	  to	  have	  co-­‐evolved	  with	  one	  another,	  as	  well	  as	  522	   the	  whole	  regulatory	  network	  [99].	  	  523	   	  524	   To	  date,	  vast	  majority	  of	  publications	  have	  focused	  on	  the	  validation	  of	  a	  single	  525	   gene	   targeted	   by	   miRNA	   that	   has	   implications	   in	   different	   biological	   models.	  526	   While	   this	   has	   been	   limited	   by	   both	   our	   lack	   of	   knowledge	   and	   experimental	  527	   capabilities,	   it	   has	   certainly	   led	   to	   an	   under-­‐estimation	   of	   miRNA	   capacity	   in	  528	   modulating	  the	  entire	  regulatory	  network	  as	  a	  “master	  regulon”.	  Fortunately,	  the	  529	   recent	   advancement	   in	   next-­‐generation	   sequencing	   and	   other	   molecular	  530	   biological	   techniques,	   such	   as	   photoactivatable-­‐ribonucleoside-­‐enhanced	  531	   crosslinking	   and	   immunoprecipitation	   (PAR-­‐CLIP),	   have	   already	   improved	   our	  532	   understanding	  and	  knowledge	  in	  the	  transcriptome-­‐wide	  regulation	  of	  miRNA	  in	  533	   many	   cellular	   contexts.	   Bioinformatic	   database	   analysis	   remains	   a	   cornerstone	  534	   for	   the	  predictive	  analysis	  of	  miRNAs	  and	   their	   targets	  and	  will	   continue	   to	  be	  535	   used	   to	   understand	   how	   miRNA	   can	   act	   beyond	   a	   single	   gene	   to	   regulate	   an	  536	   entire	  network	  [100].	  Careful	  data-­‐mining	  procedures	  and	  the	  use	  of	  a	  systems	  537	   biology	  approach	  will	  conserve	  efforts	  from	  validating	  all	  of	  the	  predicted	  targets	  538	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and	  focusing	  on	  the	  pathway	  predicted	  to	  be	  affected	  by	  the	  specific	  miRNA	  and	  539	   the	   corresponding	   regulators	   involved.	   Additionally,	   when	   regarding	   the	  540	   timeframe	  and	  strength	  of	  miRNA	  regulation,	  our	  current	  knowledge	   is	  greatly	  541	   limited	   by	   the	   use	   of	   existing	   non-­‐physiological	  methodology	   that	  manipulates	  542	   endogenous	   miRNA	   expression	   in	   cell-­‐based	   systems.	   Furthermore,	   it	   is	  543	   important	   to	  note,	   that	   in	  most	  cases,	  owing	  to	  direct	  gene	  amplification	  of	   the	  544	   miRNA	  region	  or	  altered	  expression	  of	  the	  transcription	  factors	  responsible	  for	  545	   regulating	   miRNA	   expression,	   miRNAs	   levels	   during	   disease	   pathogenesis	   are	  546	   aberrantly	  expressed	  [96].	  547	   	  548	   The	   plethora	   of	   current	   evidence	   outlined	   in	   this	   review	   identifies	  miRNAs	   as	  549	   “master	  controllers”	  of	  intracellular	  signaling	  pathways	  in	  many	  disease	  models	  550	   and	  in	  the	  era	  of	  new	  therapies	  against	  miRNA,	  this	  evidence	  highlights	  them	  as	  551	   powerful	   targets	   for	   therapeutic	   development	   with	   highly	   significant	   clinical	  552	   applications.	   In	   many	   of	   the	   studies	   covered	   in	   this	   review,	   manipulation	   of	  553	   endogenous	  miRNA	   levels	   by	   chemically	   synthesized	   analog	   or	   inhibitor	   could	  554	   revert	  the	  phenotype	  caused	  by	  the	  dysregulated	  miRNA,	  and	  therefore	  provide	  555	   the	   proof-­‐of-­‐principle	   for	   potential	   drug	   development.	   While	   therapeutic	  556	   development,	  from	  “bench	  to	  bedside”	  is	  a	  long,	  arduous	  and	  expensive	  process,	  557	   recent	   advances	   with	   the	   development	   of	   the	   first	   miRNA-­‐targeting	   drug,	  558	   miravirsen,	  (miR-­‐122	  targeting	  locked-­‐nucleic	  acid	  (LNA)-­‐modified	  inhibitor	  for	  559	   treatment	  of	  hepatitis	  C	  virus	  infection,	  currently	  in	  phase	  2	  clinical	  trial),	  have	  560	   brought	   the	   entire	  miRNA	   research	   community	   closer	   to	   therapeutic	   solutions	  561	   than	  ever	  before	   [101].	  Another	  miRNA-­‐based	  drug,	  MRX34,	   is	   the	   first	  miRNA	  562	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mimic	   for	   miR-­‐34	   and	   has	   entered	   phase	   1	   trial	   for	   treatment	   of	   HCC	   [102].	  563	   These	  outstanding	  advances	  demonstrate	  that	  miRNA	  are	  promising	  targets	  for	  564	   therapeutic	   intervention	   and	   with	   our	   advanced	   understanding	   of	   their	  565	   regulation	  of	  different	  cellular	  pathways	  and	  disease	  pathogenesis,	  it	  is	  expected	  566	   more	  pre-­‐clinically	   validated	  drugs	  will	   enter	   clinical	   trials	   and	  be	  used	   in	   our	  567	   actual	  daily	  clinical	  practice.	  	  568	   	  569	  
Conclusion	  570	   	  571	   This	   article	   has	   reviewed	   how	   miRNAs	   potently	   act	   as	   novel	   regulators	   of	  572	   classically	   known	   inhibitors	   of	   the	   JAK-­‐STAT,	   NF-­‐κB	   and	   TGFβ	   signaling	  573	   pathways.	   We	   now	   have	   a	   much	   deeper	   understanding	   of	   the	   way	   in	   which	  574	   miRNAs	   regulate	   many	   pathological	   diseases	   and	   normal	   developmental	  575	   processes.	  More	  importantly,	  we	  have	  identified	  a	  reiterating	  concept,	  whereby	  576	   miRNAs	  bind	  3’UTRs	  of	  their	  target	  irrespective	  of	  the	  protein	  coding	  sequence,	  577	   and	   regulate	   multiple	   targets,	   which	   usually	   work	   at	   different	   levels	   of	   the	  578	   signaling	   cascade,	   within	   the	   same	   signaling	   pathway.	   This	   allows	   miRNA	   to	  579	   provide	  another	  layer	  of	  signaling	  regulation,	  in	  order	  to	  achieve	  maximal	  effect	  580	   and	   avoid	   detrimental	   responses	   to	   stimuli.	   With	   this	   concept	   in	   mind,	   it	   is	  581	   essential	   for	   future	   research	   of	   miRNA-­‐target	   identification	   to	   consider	   the	  582	   regulation	   network	   (or	   regulon)	   of	   specific	   miRNA,	   in	   order	   to	   achieve	   total	  583	   understanding	   of	   the	   mechanism	   of	   any	   cellular	   process.	   More	   advanced	  584	   techniques	   can	   reveal	   the	   transcriptome-­‐wide	   regulation	   of	  miRNAs	   should	   be	  585	   considered	  a	  standard	  and	  essential	  approach.	  This	  not	  only	  takes	  the	  concept	  of	  586	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a	   single	   miRNA	   regulating	   different	   targets	   within	   the	   same	   pathway	   into	  587	   account,	   but	   also	   provides	   a	   bigger	   picture	   how	  miRNA	   can	   regulate	   different	  588	   targets	  among	  different	  signaling	  pathways.	  589	   	  590	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  1024	   Fig.1	  Biogenesis	  of	  microRNA.	  In	  the	  nucleus,	  miRNA	  is	  either	  transcribed	  from	  1025	   its	  own	  promoter	  in	  intergenic	  region	  or	  processed	  from	  the	  intronic	  region	  of	  a	  1026	   coding	  gene	  as	  a	  primary	  transcript	  (pri-­‐miRNA).	  It	  is	  processed	  by	  an	  RNase	  III-­‐1027	   type	   endonuclease	   family	   protein	   Drosha,	   with	   an	   accessory	   dsRNA-­‐binding	  1028	   protein	  DGCR8,	  into	  a	  precursor	  molecule	  (pre-­‐miRNA)	  with	  stem-­‐loop	  structure	  1029	   of	  around	  60-­‐70nt	  in	  length	  and	  a	  2nt	  overhang	  at	  the	  3’	  end.	  It	  is	  then	  exported	  1030	   to	  the	  cytoplasm	  by	  a	  transport	  protein	  Exportin-­‐5	  .	  In	  the	  cytoplasm,	  pre-­‐miRNA	  1031	   is	   further	   processed	   by	   another	   RNase	   III-­‐type	   endonuclease	   family	   protein	  1032	   Dicer,	   in	   some	   cases	   also	   with	   the	   help	   of	   accessory	   dsRNA-­‐binding	   proteins	  1033	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PACT	   and	   TRBP,	   into	   a	   dsRNA	   duplex	   of	   19-­‐21nt	   base	   pair	   region	   and	   a	   2nt	  1034	   overhang	  at	  each	  3’	  end.	  One	  of	  the	  two	  strand	  (guide	  strand)	  from	  this	  miRNA	  1035	   duplex	  is	  loaded	  onto	  RISC	  complex	  to	  effect	  its	  gene	  silencing	  function.	   	  1036	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  1037	   	  1038	   Fig.2	  Regulation	  of	  key	  regulators	  of	  cellular	  pathways	  by	  miRNAs.	  Left:	  JAK-­‐1039	   STAT	  pathway.	  Binding	  of	  cytokine	  to	  its	  cognate	  receptor	  pair	  activates	  and	  1040	   phosphorylates	  receptor-­‐associated	  JAK	  kinase	  which	  then	  phosphorylates	  1041	   downstream	  transcription	  factor	  STATs.	  Activated	  STATs	  dimerize	  and	  expose	  1042	   nuclear	  localization	  signal	  to	  enter	  nucleus	  and	  promote	  transcription	  from	  1043	   promoter	  carrying	  interferon-­‐stimulated	  responsive	  element	  (ISRE)	  or	  IFN-­‐γ	  1044	   activated	  sequence	  (GAS).	  SOCS	  proteins	  negatively	  regulate	  JAK	  kinase	  by	  1045	   blocking	  the	  binding	  with	  STATs	  and	  promoting	  the	  degradation	  of	  cytokine	  1046	   receptors;	  and	  PIAS	  proteins	  negatively	  regulate	  STAT	  transcription	  factors	  by	  1047	   blocking	  its	  binding	  to	  DNA	  and	  recruiting	  corepressor	  to	  inhibit	  transcription.	  1048	   Both	  SOCS	  and	  PIAS	  are	  under	  tight	  regulation	  by	  miRNAs.	  Middle:	  	  NF-­‐κB	  1049	   pathway.	  Both	  canonical	  and	  non-­‐canonical	  NF-­‐κB	  pathway	  are	  activated	  1050	   through	  similar	  mechanism.	  Under	  unstimulated	  condition,	  the	  activity	  of	  NF-­‐κB	  1051	   is	  suppressed	  by	  an	  inhibitory	  signal	  (canonical:	  inhibitor	  of	  κB	  (IκB);	  non-­‐1052	   canonical:	  ankyrin	  repeats	  on	  p100).	  To	  remove	  this	  inhibitory	  constrain,	  the	  1053	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inhibitory	  signal	  needs	  to	  be	  labeled	  by	  K48-­‐polyubiquitin	  chain	  and	  targeted	  to	  1054	   proteosomal	  processing.	  Prior	  to	  K48-­‐polyubiquitination	  by	  E3	  ligase,	  the	  target	  1055	   protein	  must	  be	  phosphorylated	  by	  an	  NF-­‐κB-­‐activating	  kinase,	  also	  known	  as	  1056	   mitogen-­‐activating	  protein	  kinase	  (MAPK)	  (for	  example,	  canonical:	  IκB	  kinase	  1057	   (IKK);	  non-­‐canonical:	  NF-­‐κB-­‐inducing	  kinase	  (NIK).	  In	  order	  to	  become	  activated	  1058	   to	  mediate	  downstream	  phosphorylation	  event,	  MAPK	  needs	  to	  be	  1059	   phosphorylated	  by	  an	  upstream	  kinase,	  also	  known	  as	  MAPK	  kinase	  (MAPKK)	  1060	   (for	  example	  TGFβ	  activated	  kinase-­‐1	  (TAK1)).	  This	  activating	  phosphorylation	  1061	   can	  be	  removed	  by	  protein	  phosphatase	  PP2A/C.	  Like	  MAPK,	  activation	  of	  1062	   MAPKK	  requires	  the	  phosphorylation	  of	  another	  upstream	  kinase,	  also	  known	  as	  1063	   MAPKK	  kinase	  (MAP3K).	  MAP3K	  can	  be	  activated	  by	  K63-­‐polyubiquitination	  in	  1064	   response	  to	  external	  stimuli.	  In	  terms	  of	  tumor	  necrosis	  factor	  (TNF)	  stimulation,	  1065	   the	  MAP3K	  protein,	  receptor-­‐interacting	  protein	  (RIP)1	  kinase,	  can	  be	  1066	   deactivated	  by	  deubiquitinase	  A20,	  as	  well	  as	  other	  A20-­‐related	  proteins,	  1067	   including	  its	  binding	  partner	  Ring	  Finger	  Protein	  11	  (RNF11)	  	  as	  well	  as	  	  another	  1068	   deubiquitinase	  CYLD,	  by	  removing	  its	  K63-­‐polyubiquitin	  chain	  and	  recruiting	  E3	  1069	   ligase	  to	  tag	  a	  K48-­‐polyubiquitin	  chain	  to	  promote	  its	  degradation.	  All	  these	  1070	   regulators,	  A20,	  RNF11,	  CYLD,	  and	  PP2A/C,	  can	  be	  regulated	  by	  miRNAs.	  Right:	  1071	   TGFβ	  pathway.	  Binding	  of	  TGFβ	  to	  its	  cognate	  receptors	  phosphorylates	  and	  1072	   activates	  receptor	  Smad	  (R-­‐Smad)	  proteins,	  such	  as	  Smad2	  and	  3.	  R-­‐Smad	  1073	   proteins	  bind	  other	  coactivator	  and	  translocate	  into	  nucleus	  to	  drive	  1074	   transcription	  from	  promoter	  with	  Smad-­‐binding	  element	  (SBE).	  Activation	  of	  R-­‐1075	   Smad	  proteins	  can	  be	  inhibited	  by	  inhibitory	  Smad	  (I-­‐Smad)	  such	  as	  Smad7	  1076	   through	  direct	  blockage	  of	  receptor	  and	  recruitment	  of	  other	  deactivating	  1077	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enzymes	  such	  as	  Smad	  ubiquitin	  regulatory	  factor	  (Smurf)	  E3	  ligase.	  TGFβ	  is	  1078	   normally	  secreted	  in	  a	  closed	  immature	  form	  into	  the	  extracellular	  matrix.	  	  1079	   Glycoprotein	  A	  repetitions	  predominant	  protein	  (GARP)	  expressed	  by	  T	  1080	   regulatory	  (Treg)	  cells	  can	  facilitate	  the	  maturation	  of	  	  TGFβ,	  thus	  acting	  as	  a	  1081	   positive	  regulator	  of	  the	  pathway.	  I-­‐Smad,	  Smurf	  and	  GARP	  can	  be	  regulated	  by	  1082	   miRNAs.	  miRNAs	  that	  can	  regulate	  multiple	  cellular	  targets	  from	  the	  same	  1083	   signaling	  pathway	  are	  underlined.	  1084	  
